| Author, year |
N |
Therapy Regimen |
Follow-up Period |
| Lenz 2004[10] |
240 |
E: CHOP×(4-6)cyc, Dex + BEAM, TBI, CY |
4.2 years |
| C: CHOP×(4-6)cyc , CHOP×2cyc + IFNα |
| Sebban 2006 [11] |
401 |
E: CHOP×4cyc, CY, VP16, TBI |
7.7 years |
| C: CHTP×12cyc+ IFNα |
| Ladetto 2008[9] |
134 |
E: (APO±DHAP)×2cyc, R×2cyc, CY±R×2cyc |
4.3 years |
| C: CHOP×6cyc + R×(4-6)cyc |
| Gyan 2009 [12] |
166 |
E: VCAP×3cyc, DHAP×3cyc or IMVP16, TBI, CY |
9 years |
| C: CHVP×12cyc+ IFNα-2b |
Abbreviations: CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; cyc: cycles, Dex: dexamethasone; BEAM: BCNU, melphalan, etoposide, cytarabine; TBI:
total body irradiatioin; CY: cyclophosphamide; CHTP: cyclophosphamide,doxorubicin, teniposide, prednisone; APO: doxorubicin, vincristine, prednisone; DHAP: dexamethasone,
high dose of cytarabine, and cisplatin. R: rituximab; VCAP: vindesine, cyclophosphamide, doxorubicin, prednisone; IMVP16: ifosfamide, methotrexate, and
VP-16; CHVP: cyclophosphamide, doxorubicin, vepeside, prednisone. |
